Ivax Corporation has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for fluconazole tablets in 50, 100, 150, and 200 mg dosage strengths. Fluconazole is the generic equivalent of Diflucan, an antifungal agent marketed by Pfizer to treat yeast infections. U.S. sales for fluconazole tablets were $475 million during 2003.
Ivax continues its aggressive program to increase the number of products in its generic portfolio.